跳至主要内容
临床试验/NCT04149418
NCT04149418已完成不适用

Anti-inflammatory Activity of Yogurt Mediated by the Intestine

University of Wisconsin, Madison2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2021年10月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
40
试验地点
2
主要终点
Change in Th17 proportion

研究概览

简要总结

The objective of this study is to conduct a randomized cross-over dietary intervention in adult women who are overweight or obese to compare how yogurt and a control food affect biomarkers of inflammation and intestinal health.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
None

入排标准

年龄范围
21 Years 至 55 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • healthy premenopausal women age 21-55
  • BMI ≥ 25 kg/m2
  • not taking medication to control hypertension (e.g. anti-hypertensives or diuretics)
  • resting blood pressure <140/90 mmHg
  • stable body weight for past two months
  • willing to maintain a normal exercise level (in general)
  • willing to avoid exercise and smoking (or other forms of nicotine intake) for 24 h prior to blood collection
  • willing to avoid caffeine for 12 h before study visits
  • willing to fast 12 h prior to study visits
  • willing to avoid dietary supplements, yogurt and probiotic-containing foods (as necessary) and consume 12 oz. of yogurt and the control food per day (as necessary) for the duration of the study

排除标准

  • self-reported previous diagnoses of an inflammatory disease (e.g. inflammatory bowel disease, asthma, arthritis), CVD, diabetes, current cancer treatment (i.e., chemotherapy, radiation therapy)
  • have used oral antibiotics in the prior 21 days before sample collection
  • actively trying to lose weight
  • regularly taking anti-inflammatory drugs
  • vegetarian or allergic to soy or dairy
  • are pregnant, lactating, or trying to become pregnant

结局指标

主要结局

Change in Th17 proportion

时间窗: Baseline, Week 4, Week 8, Week 12

Change in proportions of circulating Th17 cells (change in control vs. change in yogurt)

次要结局

  • Change in Treg subpopulation(Baseline, Week 4, Week 8, Week 12)
  • Change in Th17 subpopulation (IL-17A+ IFNδ+)(Baseline, Week 4, Week 8, Week 12)
  • Change in plasma tumor necrosis factor alpha (TNF-alpha)(Baseline, Week 4, Week 8, Week 12)
  • Change in plasma interleukin-17A (IL-17A)(Baseline, Week 4, Week 8, Week 12)
  • Change in fecal interleukin 1 alpha (IL-1alpha)(Baseline, Week 4, Week 8, Week 12)
  • Change in Th17 subpopulation (IL-17A+ FoxP3+)(Baseline, Week 4, Week 8, Week 12)
  • Change in plasma interleukin-22 (IL-22)(Baseline, Week 4, Week 8, Week 12)
  • Change in plasma interleukin-10 (IL-10)(Baseline, Week 4, Week 8, Week 12)
  • Change in retinoic acid receptor-related orphan nuclear receptor gamma T (RORgammaT) expression(Baseline, Week 4, Week 8, Week 12)
  • Change in Treg proportion(Baseline, Week 4, Week 8, Week 12)
  • Change in plasma interferon gamma (IFN-gamma)(Baseline, Week 4, Week 8, Week 12)
  • Change in plasma interleukin-4(Baseline, Week 4, Week 8, Week 12)
  • Change in plasma transforming growth factor beta (TGF-beta)(Baseline, Week 4, Week 8, Week 12)
  • Change in Forkhead box P3 (FoxP3) expression(Baseline, Week 4, Week 8, Week 12)
  • Change in fecal calprotectin(Baseline, Week 4, Week 8, Week 12)
  • Change in Th17 subpopulation (IL-17A+ TNFα+)(Baseline, Week 4, Week 8, Week 12)
  • Change in Th17 subpopulation (IL-17A+ IL-10+)(Baseline, Week 4, Week 8, Week 12)
  • Change in fecal tumor necrosis factor alpha (TNF-alpha)(Baseline, Week 4, Week 8, Week 12)
  • Change in fecal interleukin 1beta (IL-1beta)(Baseline, Week 4, Week 8, Week 12)
  • Change in fecal interleukin-17A (IL-17A)(Baseline, Week 4, Week 8, Week 12)
  • Change in Th17 subpopulation (IL-17A+ IL-22+)(Baseline, Week 4, Week 8, Week 12)
  • Change in plasma interleukin-6 (IL-6)(Baseline, Week 4, Week 8, Week 12)
  • Change in fecal interleukin-6 (IL-6)(Baseline, Week 4, Week 8, Week 12)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验